arrow
R

Roberta Noberini

European Institute of Oncology
H指数:27
被引数:2,107

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity

化疗诱导衰老通过降低EZH2活性促进急性髓系白血病的免疫原性

2026-09-040
OA
Immunological biomarkers for precision stereotactic body radiation therapy in early-stage non-small cell lung cancer: a systematic review

精准立体定向体部放射治疗早期非小细胞肺癌的免疫学生物标志物:一项系统综述

2026-07-240
OA
Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma

表观蛋白质组学分析鉴定组蛋白H4高度乙酰化为胸膜间皮瘤的预后标志物

2026-07-190
OAAI
TCA cycle rewiring underpins histone acetylation sourcing and cell-fate transitions during exit from naive pluripotency

三羧酸循环重编程支持表观遗传组蛋白乙酰化来源和细胞命运转变在退出原始多能状态期间

2026-04-240
OAAI
Palmitate-induced mitochondrial damage restricts histone acetylation in CD8 T cells to impair antitumor immunity

棕榈酸诱导的线粒体损伤限制了CD8 T细胞中的组蛋白乙酰化,从而损害抗肿瘤免疫。

2026-03-270
PRE
Optimized Super-SILAC Normalization Enables Enhanced Profiling of Histone Post-Translational Modification Changes Associated with Microbiota and Acute Inflammation

优化超SILAC标准化方法可增强对与微生物群和急性炎症相关组蛋白翻译后修饰变化的表征

2026-01-010
OA
A histone-centric multi-omics study shows that increased H3K4 methylation sustains triple-negative breast cancer phenotypes

一项以组蛋白为中心的多组学研究显示,H3K4甲基化水平的增加维持了三阴性乳腺癌表型。

2025-09-300
OAAI
HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy

ITF3756通过抑制HDAC6来调节PD-L1表达和单核细胞表型:对一种有前景的免疫检查点阻断联合治疗方案的启示

2025-05-130
OA
Multiscale modeling uncovers 7q11.23 copy number variation-dependent changes in ribosomal biogenesis and neuronal maturation and excitability
2024-07-152
OAAI
Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer
2024-03-298
OAAI
Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells

长期多模态记录揭示了休眠乳腺癌细胞的表观遗传适应途径

2024-03-267
OAAI
Biomarkers of response and progression to Pembrolizumab and Vorinostat combination in late-stage squamous cell carcinoma patients of different locations included in the PEVOsq basket trial
2024-03-220
PRE
Acetyl-CoA production by Mediator-bound 2-ketoaciddehydrogenases boosts de novo histone acetylation and is regulated by nitric oxide
2024-03-011
OA